Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMCAP: Cytoreductive Radical Prostatectomy + Best Systemic Therapy in Metastatic Prostate Cancer
NCT03456843Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Mar 2018
- Primary completion
- Mar 2027
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Yale University. Primary endpoint: Failure-Free Survival at 2 years. Started Mar 2018; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03456843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03456843.